BostonSight manufactures two scleral lenses, the PROSE device and BostonSight SCLERAL lens, that have been used for decades to treat dry eye and ocular surface disease. In this video from the Anterior Innovation Showcase at OIS XV, chief medical officer Daniel Brocks, MD, explains how the company is investigating the devices—which do not touch the cornea but actually contact the sclera and vault the cornea to create a fluid reservoir on the eye—to deliver drugs to the ocular surface.